Fostering Trade in Health in Asia

Dr. Deborah Elms

May 25, 2016

FT Asia Healthcare & Life Sciences Summit, Singapore

elms@asiantradecentre.org



Trans-Pacific Partnership (TPP) Agreement

- TPP= Most consequential trade deal in decades
- Twelve countries, three continents, diverse levels of economic development
 - Australia, Brunei, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore, United States, and Vietnam
- Negotiations completed on Oct 5, 2015
 Full texts and schedules now available online
- Accession clause for future expansion
 - Korea, Hong Kong, China, Taiwan, Philippines, Columbia, Costa Rica, Panama?



Current TPP Twelve



What's Different About the TPP?

- TPP is broader:
 - Covers markets for all goods (including sensitive items), services, investment, government procurement, e-commerce with meaningful promises for opening
 - 30 chapters included in agreement, 8000+ pages
- TPP is deeper:
 - Has new rules for areas like intellectual property, food and food safety (SPS), standards (TBT), environment, labor, competition, customs, etc.
- Shared norms:
 - Every member has same commitments (just longer time frames for some members to implement deal)



What Happens When the TPP Starts?

- Sensitive products often excluded or carved out of trade agreements--TPP does not
- Tariffs will drop to 0 on 90% of *all* goods trade between the TPP members on day one, rising to 98% quite quickly
- Faster, smoother trade across borders
- Services and investment dramatically opened, more transparency, protections
- Some new standards included
- E-commerce and digital trade rules
- Government procurement markets opened
- Legally binding



Benefits for Health: Devices

- Medical devices often considered sensitive and excluded: TPP does not
 - Tariff reductions (often to 0 and often on day 1)
 - Applies to all TPP members (even if specific commitments vary across members)
- New rules in TBT chapter (8) and annex (8E) for devices specifically
 - Mutual recognition agreements/arrangements
 - Fewer duplicative tests
 - Greater transparency
- Interesting new options for device/pharma nexus?

Benefits for Health: Health Services

- Normally, health services closed to foreign providers
- But TPP opens health services—hospitals, clinics, diagnostic tests, nursing homes, hospice, specialist care, etc.
 - All services opened, unless restrictions listed
- TPP opens to TPP member firms
 - May still need licenses, immigration
 - For private medical services, not public facilities
- Services chapter (10) also includes temporary entry of business providers (12)



Benefits for Health: Pharma

- Extended patent protections in IP chapter (18) and annexes
 - Issue for Americans on biologics data protection
 - Dramatically longer (0 years to 5+ years protection) for most member governments
 - In practice, TPP parties follow US approvals anyway
- Also see TBT chapter 8, esp annex 8C on pharmaceuticals that includes:
 - Specific rules to be followed for who can regulate (and who cannot)
 - Use science, not sales or financial data
 - Greater transparency in decisionmaking, esp for marketing authorization
 - Sets out some conditions for marketing authorization

0

Right to Regulate

- In the TPP, like all trade agreements, government retains full right to regulate for:
 - Human, animal, plant life and health
 - Security and defense
 - Public interest
- Implementation will be worth watching agreement provides framework, but details will matter
- TPP cannot undermine existing commitments in other trade agreements (like World Trade Organization)



TPP Timelines

- Complication: approval in the United States
 - Trade Promotion Authority (TPA) has some specific deadlines that must be followed
 - Agreement signed Feb 4, 2016
 - Could be submitted to Congress: lame duck session in Nov/Dec 2016; or 2018?
- Implementation:
 - 1. All 12 approve in 2 years: 60 days later
 - 2. US+Japan+4 more members inside 2 years: automatic EIF on April 4, 2018
 - 3. US+Japan+4 more after April 2018: 60 days later

TPP Benefits for Health

- The TPP provides substantial benefits for many sectors
- But health may provide important new opportunities
 - Focus has largely been on negatives (especially biological data protection length)
 - Has obscured many other elements of agreement for health industry and health providers
- Implementation will be important
 - Especially for pharmaceuticals—how medicines are now approved for formulary countries? IP protections? IP enforcement?
 - Early stages may be uneven in some TPP members



The Asian Trade Centre is the premier regional thought leader, advocate and educator for trade in Asia

For more information, please contact:

Deborah Elms Executive Director Asian Trade Centre Singapore www.asiantradecentre.org

